Real-life efficacy and safety of secukinumab: A single-center, retrospective observational study with 52-week follow-up
Background: Secukinumab is a fully human monoclonal antibody against interleukin-17. Phase III trials have shown encouraging results in chronic plaque psoriasis. The real-life data for safety and efficacy of secukinumab are limited. Methodology: This was a retrospective, single-center, observational...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Indian Journal of Drugs in Dermatology |
| Subjects: | |
| Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2019;volume=5;issue=1;spage=14;epage=18;aulast=Neema |